A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are important regulators of metabolism, making their receptors (GLP-1R and GIPR) attractive targets in the treatment of type 2 diabetes mellitus (T2DM). GLP-1R agonists are used clinically to treat T2DM but the us...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Zamel, Noura, Al-Sabah, Suleiman, Luqmani, Yunus, Adi, Lobna, Chacko, Siby, Schneider, Tom Dario, Krasel, Cornelius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678630/
https://www.ncbi.nlm.nih.gov/pubmed/31330984
http://dx.doi.org/10.3390/ijms20143532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678630/
https://www.ncbi.nlm.nih.gov/pubmed/31330984
http://dx.doi.org/10.3390/ijms20143532

Ejemplares similares